Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11224081 | 0.95 | LMNA (0.33) | LMNA | |
| SCHEMBL76560 | 0.92 | LMNA (0.32) | LMNA | |
| Hydrochloric Acid SCHEMBL7459719 | 0.90 | PABPC1 (0.32) | LMNA | |
| SCHEMBL7074888 | 0.81 | ALDH1A1 (0.39) | — | |
| SCHEMBL9051047 | 0.80 | CYP1A2 (0.44) | LMNA | |
| SCHEMBL5392162 | 0.78 | ORAI1 (0.38) | LMNA | |
| SCHEMBL1977562 | 0.78 | LMNA (0.31) | LMNA | |
| Hydrochloric Acid SCHEMBL4432602 | 0.77 | — | — | |
| SCHEMBL3289331 | 0.75 | CA1 (0.30) | — | |
| SCHEMBL4731836 | 0.75 | ALOX15 (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| WO-2008061238-A2 | PROCESSES FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| JP-10130232-A | — | — | None | — | — | JP | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| US-20200223825-A1 | INHIBITORS OF GLUTAMINYL CYCLASE | VIVORYON THERAPEUTICS N.V (DE) | 2020-07-16 | — | — | US | disclosed |
| EP-3461819-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019063414-A1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2019-04-04 | — | — | WO | disclosed |
| EP-3461819-A1 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2019-04-03 | — | — | EP | disclosed |
| US-20180340174-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | NANOCORE APS (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-3218479-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | Nanocore ApS (DK) | 2017-09-20 | — | — | EP | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008061238-A2 | PROCESSES FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| JP-H10130232-A | AZETIDINONE DERIVATIVE AND ITS PRODUCTION | JAPAN TOBACCO INC | 1998-05-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | LMNA 518/4885 |
| US-20200223825-A1 | INHIBITORS OF GLUTAMINYL CYCLASE | QPCT, QPCTL, GLUL | LMNA 3967/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | LMNA 3967/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | LMNA 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.